10041-04-0

Basic information

• Product Name: Phenol, 2-(1H-imidazol-1-yl)-
• CAS NO: 10041-04-0
• Molecular Formula: C9H8N2O
• Molecular Weight: 160.175
• Mol File: 10041-04-0.mol
• Article Data: 18

Chemical Properties

• CAS DataBase Reference: Phenol, 2-(1H-imidazol-1-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 2-(1H-imidazol-1-yl)-(10041-04-0)
• EPA Substance Registry System: Phenol, 2-(1H-imidazol-1-yl)-(10041-04-0)

Safety Data

• Hazardous Substances Data: 10041-04-0(Hazardous Substances Data)

Upstream product

• 288-32-4 1H-imidazole 
• 533-58-4 2-Iodophenol 
• 5720-06-9 2-Methoxyphenylboronic acid 
• 578-57-4 2-bromoanisole 
• 288-42-6 oxazol 
• 75-09-2 dichloromethane 
• 90-04-0 2-methoxy-phenylamine 
• 529-28-2 4-iodoanisol 
• 95-56-7 2-hydroxybromobenzene 
• 10040-93-4 1-(2-methoxyphenyl)-imidazole 
• 78009-23-1 1-(3,5-di-tert-butyl-2-hydroxyphenyl)imidazole 

Downstream Products

• 61292-76-0 2-(1-imidazolyl)-thiophenol 
• 71289-27-5 Allyl-[2-(1-imidazolyl)-phenyl]-ether, hydrochloride 
• 1620294-17-8 tert-butyl ((5-((2-(1H-imidazol-1-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methyl)carbamate 
• 1620294-19-0 (5-((2-(1H-imidazol-1-yl)phenoxy)methyl)-4,5-dihydroisoxazol-3-yl)methanamine hydrochloride 

Relevant articles and documents

ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME

The invention relates to an organometallic compound, an organic light-emitting device including the same. The organometallic compound is represented by Formula 1. The organic light-emitting device includes a first electrode, a second electrode, and an org

HERBICIDAL COMPOUNDS

The present invention relates to compounds of Formula (I) or an agronomically acceptable salt of said compounds wherein Q, R1, R2, n and m are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling weeds, in particular in crops of useful plants.

Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8

The latency-associated nuclear antigen (LANA) is required for latent replication and persistence of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. It acts via replicating and tethering the virus episome to the host chromatin and exerts other functions. We conceived a new approach for the discovery of antiviral drugs to inhibit the interaction between LANA and the viral genome. We applied a biophysical screening cascade and identified the first LANA binders from small, structurally diverse compound libraries. Starting from a fragment-sized scaffold, we generated optimized hits via fragment growing using a dedicated fluorescence-polarization-based assay as the structure-activity-relationship driver. We improved compound potency to the double-digit micromolar range. Importantly, we qualified the resulting hit through orthogonal methods employing EMSA, STD-NMR, and MST methodologies. This optimized hit provides an ideal starting point for subsequent hit-to-lead campaigns providing evident target-binding, suitable ligand efficiencies, and favorable physicochemical properties.